Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus azacitidine in acute myeloid leukemia
ACTRN12610001031055Phase 2Recruiting
- Sponsor
- The Alfred Hospital
- Start
- Mar 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus and azacitidine in acute myeloid leukemia (AML), sponsored by The Alfred Hospital. Primary endpoint: Safety and tolerability. Started Mar 2010; status: recruiting.
02
Drugs
everolimusazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12610001031055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610001031055.